Publications

Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, Bonnefoi H, Knudsen E, Im SA, DeMichele A, Van't Veer L, Kim SB, Bear H, McCarthy N, Rhiem K, Turner N, Witkiewicz A, Rojo F, Filipits M, Martin LA, Fasching PA, Schem C, Becker K, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Liu Y, Valota O, Felder B, Weber K, Nekljudova V, Loibl S. BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis. JCO precision oncology. 2025. PMID: 40209141

Yadav S, Tuchayi AM, Moradpour M, Jiang F, Juarez R, de Kouchkovsky I, Flavell RR, Aggarwal RR, Hope TA. Pre- or post-chemotherapy: effect on PSMA uptake. EJNMMI research. 2025. PMID: 40192880

DeBoer RJ, Wabl CA, Mushi BP, Uwamahoro P, Athanas R, Ndoli DA, Rugengamanzi E, Ngoma M, Tuyishime H, Mtei D, Nsabimana N, Van Loon K, Sanders JJ, Sudore RL, Cubaka VK. A scoping review of clinical communication in cancer care in Africa. The oncologist. 2025. PMID: 40212023

Doruk YU, Diolaiti ME, Ashworth A, Talele TT. Discovery of a Novel [6-6-5-5-6] Pentacyclic Tetrahydrocyclopentaphthalazinone as a Promising PARP Inhibitor Scaffold. ACS medicinal chemistry letters. 2025. PMID: 40365384

Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Patel PA, Collins RH, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics T, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Koenig KL, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial. Blood cancer journal. 2025. PMID: 40180903

Tan CR, Asoori S, Huang CY, Brunaldi L, Popat R, Kastritis E, Martinez-Lopez J, Bansal R, Silva Corraes AM, Chhabra S, Parrondo R, Ailawadhi S, Fotiou D, Dimopoulos MA, Yong K, Mactier C, Lau C, Corona M, Marin AJS, Mian H, Durie BG, Usmani SZ, Martin TG, Lin Y. Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study. Blood cancer journal. 2025. PMID: 40175336

Ebbert JO, Hawk ET, Chambers CV, Tempero MA, Fishman EK, Ravenell JE, Beer TM, Rego SP. Multi-cancer early detection tests: Attributes for clinical implementation. Cancer biomarkers : section A of Disease markers. 2025. PMID: 40171802

Gritti I, Wan J, Weeresekara V, Vaz JM, Tarantino G, Bryde TH, Vijay V, Kammula AV, Kattel P, Zhu S, Vu P, Chan M, Wu MJ, Gordan JD, Patra KC, Silveira VS, Manguso RT, Wein MN, Ott CJ, Qi J, Liu D, Sakamoto K, Gujral TS, Bardeesy N. Correction: DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming. Cancer discovery. 2025. PMID: 40170541

Tsai KK, Chang AY, Abouzeid CM, Aras MA, Fang Q, Bibby D, Haghighat L, Hilton JF, Daud AI, Schiller NB. Longitudinal Evaluation of Immune Checkpoint Inhibitor-Induced Fatigue Syndrome by Rest, Stress, and Speckle-Tracking Strain Echocardiography. Echocardiography (Mount Kisco, N.Y.). 2025. PMID: 40198654

Pearson ADJ, Rossig C, Mackall CL, Shah NN, Baruchel A, Daems S, Anderson J, Biondi A, Bird N, Bodmer N, Brivio E, Buechner J, Calkoen FG, Cooper T, de Rojas T, Fox E, Gardner R, Ghorashian S, Heenen D, Ifversen M, Jacoby E, Juan M, Knox L, Komanduri K, Larghero J, Locatelli F, Ludwinski D, Majzner RG, McDonough J, Minard-Colin V, Nysom K, Pappo A, Park JR, Qasim W, Quintarelli C, Rives S, Rouce RH, Scobie N, Seitz C, Tasian SK, Weigel B, Weiner S, Zwaan CM, Vassal G. New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis. The Lancet. Oncology. 2025. PMID: 40179917

Gilligan T, Lin DW, Adra N, Bagrodia A, Feldman DR, Yamoah K, Aggarwal R, Chandrasekar T, Costa D, Drakaki A, Eggener S, Emamekhoo H, Geynisman DM, Graham L, Humphrey P, Leuva H, Levine EG, Luckenbaugh A, Maughan BL, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Reichert Z, Rwigema JC, Saylor P, Shah A, Shah S, Singla N, Sircar K, VanderWeele D, Zhumkhawala A, Montgomery S, Sliker B. NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025. Journal of the National Comprehensive Cancer Network : JNCCN. 2025. PMID: 40203876

Brufsky AM, Sandin R, Stergiopoulos S, Chen C, Karanth S, Li B, Esterberg E, Makari D, Candrilli SD, Goyal RK, Rugo HS. Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2- Metastatic Breast Cancer. Cancer medicine. 2025. PMID: 40145289

Feng EM, Vo-Phamhi J, Subramanian AN, Dias M, Foye A, Vinson J, Hong JC, Freedland SJ, Alumkal JJ, Beltran H, Morrissey C, Nelson PS, Chinnaiyan AM, Aggarwal R, Small EJ, Quigley DA, Sjöström M, Zhao SG, Chen WS. Racial variation in the advanced prostate cancer genome. Prostate cancer and prostatic diseases. 2025. PMID: 40164700

Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S. A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer. Future oncology (London, England). 2025. PMID: 40159790

Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. Treatment with palbociclib and an aromatase inhibitor for people with hormone receptor-positive/ human epidermal growth factor receptor 2-negative metastatic breast cancer that has spread to the lungs or liver: a plain language summary. Future oncology (London, England). 2025. PMID: 40159782

Kotecha RR, Doshi SD, Knezevic A, Jacobi R, Woo HJ, Aggen DH, McHugh DJ, Shah NJ, Carlo MI, Keegan NM, Gayadin Y, Chaim J, Donoghue MTA, Iyer G, Lee CH, Feldman DR, Motzer RJ, Voss MH. A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma. European urology oncology. 2025. PMID: 40158923

Batchu SA, Ma Y, Yom S, Heaton C, Algazi A. CRE25-035: Vascular Endothelial Growth Factor Inhibitor-Induced Radiation Recall Tracheitis in a CASTLE Carcinoma of the Thyroid Patient. Journal of the National Comprehensive Cancer Network : JNCCN. 2025. PMID: 40154357

Middha P, Thummalapalli R, Quandt Z, Balaratnam K, Cardenas E, Falcon CJ, Margaret Lung Group P, Gubens MA, Huntsman S, Khan K, Li M, Lovly CM, Patel D, Zhan LJ, Liu G, Aldrich MC, Schoenfeld A, Ziv E. Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events. Journal for immunotherapy of cancer. 2025. PMID: 40154961

Bardia A, Pistilli B, Rugo H. Reply to: Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40153734

Wang M, Jutras G, Cullaro G, Dhruva A, Lai JC. Patterns of dietary supplement use among United States patients with steatotic liver disease: Vitamins, minerals and botanicals. World journal of hepatology. 2025. PMID: 40177193